TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum Tolerated Dose (MTD) of the Combination of Ganetespib and Ziv-aflibercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional measurement score (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Urinary Track Infection (UTI)
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained virological response of HCV at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in touch and sensory by way of change in the Semmes-Weinstein Monofilament Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in touch and sensory by way of changes in Functional Gait Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in number of satisfied/dissatisfied patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: endothelial function as measured by FMD of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum concentration of β2 microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ETDRS Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Musculoskeletal Consumer Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Regional longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of IBD patients in clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with at least one Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Interleukin 10 and 13 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FT success defined by Sorensen's index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Functional Living Index-Emesis (FLIE) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Psychomotor vigilance test Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Contrast Induced-Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Formate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Specialty Mental Health Patients Transitioned to Primary Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness of Intervention's Impact on Clinic Access
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percent of Mental Health Providers Who Use FLOW Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of hyperandrogenemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With an Adverse Event (AE) During Treatment Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Mean Percent Change in Femoral Neck Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Mean Percent Change in Femoral Trochanter Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: ITP-PAQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fall Rate
Endpoint domain: Adverse events/effects
Primary endpoint: diagnostic accuracy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in QT/QTcF intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morphine Equivalence Dosage PER DAY
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ibuprofen concentration in the CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative mortality within 3 days
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comprehensive Cardiac Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T2* Mapping Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T1 Mapping Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skeletal related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of dosing regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phasic esophageal pressure deflection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite of ischemic stroke and systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Major Bleed
Endpoint domain: Adverse events/effects
Primary endpoint: Safety tolerability assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limiting toxicity determination
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of Sensorimotor Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Pregnant Women experiencing Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of fetuses and newborns experiencing complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Bradycardia Episodes/Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time of eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of transfer to the postoperative care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recovery scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sexual Function and Satisfaction Questionnaire (SFSQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose of ABT-888
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical Global Impression of Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Adverse Events related to EDIT-101
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing procedural related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Test-retest variability of thermal thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in T2 spin parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of changes in specific clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exponential rate constant of phosphocreatine recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stress related symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abnormal concentrations of CSF biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in EEG Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in the Major Symptom Complex (MSC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Disability Quality-of-Life Questionnaire (PDQQ-S)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occlusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pharmacokinetics measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine-induced mood changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effects of topiramate on cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cardiovascular response to cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resistive index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Duration of continuous daily symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incontinence Impact Questionnaire (IIQ-7)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Any cause of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of RO7079901
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero Until End of Dosing Interval (AUC0-tau) of RO7079901
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants in Renal Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Major wound complication
Endpoint domain: Adverse events/effects
Primary endpoint: Overall hospital and malaria mortality
Endpoint domain: Mortality/survival
Primary endpoint: BOLD response to images of high-calorie foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of chronic pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in Mean Scores on the Conflicts Tactics Scale (CTS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mean Scores on the Dimensions of Anger Reactions Scale (DAR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mean Scores on the Novaco Anger Scale (NAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Progression-free survival without grade 4
Endpoint domain: Mortality/survival
Primary endpoint: HIF-1 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postreperfusion syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disaturated phosphatidylcholine (DSPC) fractional synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in urgency sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of chlamydia in women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post-operative Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue Raltegravir Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total (TIMP-2)x(IGFBP7) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Variation of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of performance status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Variation of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of the drug
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of the scanner compared to anthropometric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of the scanner compared to anthropometric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of allogeneic platelet units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Wet weight and dry weight of sputum expectorated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image findings at PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBMC cell differentiation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: acute kidney failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Observed Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Rates of pancreatic fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Confidence to Engage in HIV Prevention Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pregnancy-related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Leukocyte esterase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in FiO2 during NIV vs daytime with nasal cannula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Variability of center-of-mass movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to physician's decision to treat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pseudomonas aeruginosa strains counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physiological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Ulceration Area, Volume, Depth and Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Ankle Brachial Index (ABI)/Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diffuse Noxious Inhibitory Control Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Block Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCORing of Atopic Dermatitis (SCORAD) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of COVID19 in LT recipients
Endpoint domain: Mortality/survival
Primary endpoint: Survival and Mechanical ventilation / respiratory support
Endpoint domain: Mortality/survival
Primary endpoint: Changes in the number of microorganisms in the intestinal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in the types of microorganisms in the intestinal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tissue classification as neoplastic or non-neoplastic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lesion progression or regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychologic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Size of contralateral testis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of BIIB021
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweat chloride value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bone mineral density of the tibia and radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Biomarker Differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative rotations of bones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving American College of Rheumatology, 20% Improvement (ACR20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration of telotristat ethyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum observed concentration of telotristat ethyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve of telotristat ethyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic uptake and clearance of 18F-AV-133 tracer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of relapser patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication scores
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Integrated viral reservoir size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proviral reservoir size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Normal Physical Examination of the Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with technically feasible treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HbA1c (glycolated haemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GVHD-free, relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Self-Compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical Self-Perceptions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Completion of CRC Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of postoperative major adverse cardiocerebral events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Composite Quality Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Successful pancreaticoduodenectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chemotherapy-induced early menopause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 17 beta estradiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Menstrual activity resumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ICP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pulse transit time (PTT) estimation of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacoresistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of hydronephrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sleep latency during MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of surgical referral
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy of switching from Adalimumab to Infliximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital mortality after index surgery
Endpoint domain: Mortality/survival
Primary endpoint: Length of ICU stay after index surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Length of stay after index surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in P-wave time (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in P-wave amplitude (PAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes